Organogenesis Holdings (STU:2PQ) Operating Margin %: -190.05% (As of Mar. 2026)


STU:2PQ Organogenesis Holdings Inc STU:2PQ
67 GF Score
Price €2.12
GF Value €2.76
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Organogenesis Holdings Operating Margin %?

Organogenesis Holdings STU:2PQ -0.93% 67 Operating Margin % is -190.05% as of Mar. 2026. GuruFocus rates STU:2PQ with a GF Score™ of 67/100 and a GF Value™ of €2.76 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 955 Drug Manufacturers companies, Organogenesis Holdings ranks worse than 66.81% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Organogenesis Holdings's Operating Income for the three months ended in Mar. 2026 was €-59.6 Mil. Organogenesis Holdings's Revenue for the three months ended in Mar. 2026 was €31.4 Mil. Therefore, Organogenesis Holdings's Operating Margin % for the quarter that ended in Mar. 2026 was -190.05%.

Warning Sign:

Organogenesis Holdings Inc operating margin has been in a 5-year decline. The average rate of decline per year is -8.5%.

The historical rank and industry rank for Organogenesis Holdings's Operating Margin % or its related term are showing as below:

STU:2PQ' s Operating Margin % Range Over the Past 10 Years
Min: -24.84   Med: 3.68   Max: 15.45
Current: 1.4


STU:2PQ's Operating Margin % is ranked worse than
66.81% of 955 companies
in the Drug Manufacturers industry
Industry Median: 7.45 vs STU:2PQ: 1.40

Organogenesis Holdings's 5-Year Average Operating Margin % Growth Rate was -8.50% per year.

Organogenesis Holdings's Operating Income for the three months ended in Mar. 2026 was €-59.6 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was €5.2 Mil.


Organogenesis Holdings  (STU:2PQ) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Organogenesis Holdings Operating Margin % Related Terms


Organogenesis Holdings Operating Margin % Historical Data

* Premium members only.

The historical data trend for Organogenesis Holdings's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Organogenesis Holdings Operating Margin % Chart

Organogenesis Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.45 4.95 2.89 4.46 9.92

Organogenesis Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -23.28 -10.75 14.39 28.98 -190.05

STU:2PQ vs SIGA, ELTP, TKNO: Operating Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Organogenesis Holdings's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Organogenesis Holdings Operating Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Organogenesis Holdings's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Organogenesis Holdings's Operating Margin % falls into.


STU:2PQ
67GF Score
Organogenesis Holdings Inc STU:2PQ
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Organogenesis Holdings Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Organogenesis Holdings's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=47.712 / 480.828
=9.92 %

Organogenesis Holdings's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=-59.591 / 31.356
=-190.05 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of -190.05% mean?
Organogenesis Holdings (STU:2PQ) has a Operating Margin % of -190.05% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Organogenesis Holdings and its competitors. According to the industry distribution chart, Organogenesis Holdings ranks #638 out of 955 companies in the Drug Manufacturers industry, placing it in the top 66.8%.
Is Organogenesis Holdings' Operating Margin % too high?
Organogenesis Holdings' current Operating Margin % is -190.05%. Based on the distribution chart, Organogenesis Holdings ranks #638 out of 955 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Organogenesis Holdings has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Organogenesis Holdings' Operating Margin % compare to SIGA and ELTP?
According to the Drug Manufacturers industry distribution chart, Organogenesis Holdings ranks #638 out of 955 companies for Operating Margin %. This places Organogenesis Holdings in the lower half of its industry. The industry median Operating Margin % is 7.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.45, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Organogenesis Holdings and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Organogenesis Holdings's current Operating Margin % is -190.05%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organogenesis Holdings stock overvalued right now?
Based on GuruFocus' analysis, Organogenesis Holdings (STU:2PQ) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.76, compared to a current price of €2.12 — trading 23.2% below its estimated fair value. The current Operating Margin % is -190.05%. Organogenesis Holdings' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Organogenesis Holdings (STU:2PQ), the current Operating Margin % is -190.05% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Organogenesis Holdings (STU:2PQ) Overvalued in 2026?

Based on GuruFocus' analysis, Organogenesis Holdings stock appears to be undervalued. The current stock price of €2.12 is trading 23.2% below its estimated GF Value™ of €2.76. GuruFocus considers Organogenesis Holdings to be Modestly Undervalued.

Key valuation signals for STU:2PQ:

  • Operating Margin %: -190.05%
  • GF Value™: €2.76 vs. price of €2.12 (23.2% below fair value)
  • GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the STU:2PQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Organogenesis Holdings Business Description

Other Exchanges ORGO:USA2PQ:Germany
Address 85 Dan Road, Canton, MA, USA, 02021
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
67GF Score

Get the complete analysis for STU:2PQ

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.12
Price
€2.76
GF Value